Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.39 |
| ▸ | ABL1 | P00519 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24285951 | 0.77 | LRRK2 (0.40) | LRRK2ABL1ADORA2AADORA1ADORA2B | |
| SCHEMBL24285952 | 0.77 | LRRK2 (0.51) | LRRK2ABL1 | |
| SCHEMBL24286624 | 0.70 | LRRK2 (0.44) | LRRK2ABL1ADORA2AADORA1 | |
| SCHEMBL24285831 | 0.68 | LRRK2 (0.48) | LRRK2ABL1 | |
| SCHEMBL24286210 | 0.67 | LRRK2 (0.52) | LRRK2ABL1 | |
| SCHEMBL24286636 | 0.66 | LRRK2 (0.55) | LRRK2ABL1 | |
| SCHEMBL24285885 | 0.65 | LRRK2 (0.41) | LRRK2ABL1 | |
| SCHEMBL24286003 | 0.65 | CDK2 (0.38) | LRRK2ABL1 | |
| SCHEMBL22362945 | 0.65 | LRRK2 (0.57) | LRRK2ABL1 | |
| SCHEMBL22149192 | 0.64 | BRD4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | LRRK2 538/4885ABL1 966/4885ADORA2A 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.